345 - CCS/NATIONAL ADVISORY COMMITTEE JOINT STATEMENT ON BLOOD UTILIZATION/TRANSFUSION FOR PATIENTS WITH CARDIOVASCULAR DISEASE

Saturday, October 25, 2025

2:00pm - 3:00pm ET

Room:304AB

Target Audience: General: All cardiovascular (clinical and research) health professionals, Internists, Trainee (clinical)

Co-Chair(s)

Greg Schnell, BSP, MD, FRCPC

CLINICIAN
Libin Cardiovascular Institute
Libin Cardiovascular Institute, University of Calgary
AS

Andrew Shih, MD. FRCPC, DRCPSC, MSc (he/him/his)

Regional Medical Director, Transfusion Medicine
Hamilton Regional Laboratory Medicine Program
McMaster University

Presenter(s)

Emilie Belley-Cote, MD PhD

Cardiologist-intensivist
McMaster University
McMaster Unviersity
Ryan Lett

Saskatchewan Health Authority
University of Saskatchewan

Handouts / Images
MP

Maude Peretz-Larochelle, MD, FRCPC

CARDIOLOGIST
CCS, CANCARE
McGill University
Greg Schnell, BSP, MD, FRCPC

CLINICIAN
Libin Cardiovascular Institute
Libin Cardiovascular Institute, University of Calgary
AS

Andrew Shih, MD. FRCPC, DRCPSC, MSc (he/him/his)

Regional Medical Director, Transfusion Medicine
Hamilton Regional Laboratory Medicine Program
McMaster University

Moderator(s)

CG

Carolyn Gall Casey, BASc

Director Guidelines and Knowledge Translation
Canadian Cardiovascular Society

Planning Committee Member(s)

Greg Schnell, BSP, MD, FRCPC

CLINICIAN
Libin Cardiovascular Institute
Libin Cardiovascular Institute, University of Calgary

Workshop Description: This workshop will review the joint statement from the Canadian Cardiovascular Society (CCS)/National Advisory Committee on Blood and Blood Products regarding best practices for blood utilization and transfusion in patients with cardiovascular disease. It will provide evidence-based statements for transfusion thresholds in the setting of acute coronary syndromes. Emphasis will be placed on aligning clinical decision-making with updated national guidance to ensure patient safety and optimize outcomes.

Presentations:

Maude Peretz-Larochelle – Transfusion thresholds in ACS

Emillie Belley-Cote – Type 1 versus Type 2 MI

Emillie Belley-Cote – Review of the Evidence

Andrew Shih – Potential risks of transfusion

Ryan Lett – State of Transfusion Health

Andrew Shih – Review of central figure & comparison to what others are saying

Learning Objectives:

At the end of this session participants will be able to:

apply currently published data into an approach for blood transfusion thresholds in patients with cardiovascular disease;
evaluate the risks, benefits, and systems factors of transfusion in various cardiovascular patient populations; and
incorporate blood product management best practices, including transfusion and alternatives, into multidisciplinary cardiovascular care pathways.